

Course Number: 364

Course Title: Osteochondral Lesions of the Talus: Current Treatment Dilemmas

Location: Moscone West, Room 3014

Date & Start Time: 2/9/2012 4:00 PM

INSTRUCTORS WHO CONTRIBUTED TO THIS HANDOUT:

James W Stone, MD - 4 (Amgen Co; Johnson & Johnson; Procter & Gamble;; Pfizer);

Annunziato Amendola, MD - 1 – Arthrex, Inc., ArthroSurface; 3B – Arthrex, Inc., Zimmer; 3C – MTP Solutions; 4 – ArthroSurface, MTP Solutions

Mark Glazebrook, MD - 2 (Biomimetic; Wright Medical Technology, Inc.); 3B (Biomimetic; BioSet; Carticept; CONMED Linvatec; Smith & Nephew; Wright Medical Technology, Inc.); 5 (Biomimetic; Bioset; Cartiva; DePuy, A Johnson & Johnson Company);

Alberto Gobbi, MD - n

DISCLOSURE

Each participant in the Annual Meeting is require to disclose if he or she has received something of value from a commercial company or institution, which related directly or indirectly to the subject of their presentation: The Academy has identified the options to disclose as follows:

The codes after the name are identified as 1= Royalties from a company or supplier; 2= Speakers bureau/paid presentations for a company or supplier; 3A= Paid employee for a company or supplier; 3B= Paid consultant for a company or supplier; 3C= Unpaid consultant for a company or supplier; 4= Stock or stock options in a company or supplier; 5= Research support from a company or supplier as a PI; 6= Other financial or material support from a company or supplier; 7= Royalties, financial or material support from publishers; and n= no conflicts disclosed.

An indication of the participants disclosure appears after his or her name as does the commercial company or institution that provided the support.

The Academy does not view the existence of these disclosed interests or commitments implying bias or decreasing the value of the author's participation in the meeting.

DISCLAIMER

The material presented at this course has been made available by the AAOS for educational purposes only.

The AAOS disclaims any and all liability for injury, loss or other damages resulting to any individual attending the course and for all claims, which may arise from the use of techniques and strategies demonstrated therein. The material is not intended to represent the only methods, procedures or strategies for the situations discussed. Rather, the course is intended to present an array of approaches, views, statements and opinions which the faculty believe will be helpful to course participants.

Some drugs or medical devices demonstrated in Academy educational programs or materials have not been cleared by the FDA or have been cleared by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.

INSTRUCTORS WHO CONTRIBUTED TO THIS HANDBOOK

- James W. Stone, MD - A (Amgen Co. Johnson & Johnson, Praxair, Pfizer)
- Amunolo Amadio, MD - I (Amgen Co. Johnson & Johnson, Pfizer, J. Johnson & Johnson)
- Alan Glazebrook, MD - I (Bioninetic, Wright Medical Technology, Inc.)
- John Smith & Robert Wright Medical Technology, Inc. (Bioninetic, Biotech, Cariva, Omega, Johnson & Johnson Company)
- Albino Gobbi, MD - I

Each participant in the Annual Meeting is invited to discuss it in or has received something of value from a commercial company or organization with respect to the subject of this handout. The Academy has identified the options for disclosing such relationships as follows:

- 1 - Royalties from a company or supplier; 2 - Speaker's fees; 3 - Paid employee for a company or supplier; 4 - Stock or stock options in a company or supplier; 5 - Consultant for a company or supplier; 6 - Other financial or material support from a company or supplier; 7 - Royalties, financial or material support from publisher; and no conflict of interest.

An indication of the participant's disclosure option after the word "disclosure" is provided in the handout. The Academy does not view the existence of these disclosure interests or commitments as a conflict of interest or a bias in the value of the subject's participation in the meeting.

DISCLAIMER

The material presented in this handout is provided by the AAOS for educational purposes only. The AAOS disclaims any and all liability for any injury or damage, including any and all claims, which may arise from the use of this material. The AAOS disclaims any and all liability for any injury or damage, including any and all claims, which may arise from the use of this material. The AAOS disclaims any and all liability for any injury or damage, including any and all claims, which may arise from the use of this material.

Ankle ICL 364: Osteochondral Lesions of the Talus: Current Treatment Dilemmas

- | | |
|-----------------------------------|----------------------------------------------------------------------------|
| Speaker 1: Mark Glazebrook | Etiology, Classification, and Natural History |
| Speaker 2: James Stone | OCL Talar Dome: Treatment by Excision, Curettage, Microfracture |
| Speaker 3: A. Amendola | Osteochondral Resurfacing Techniques for Focal Lesions of the Ankle |
| Speaker 4: Alberto Gobbi | New Horizons in Treatment of OCL Talus |